Search results for "hepatic steatosis"

showing 10 items of 20 documents

Chemotherapy and Hepatic Steatosis: Impact on Postoperative Morbidity and Survival after Liver Resection for Colorectal Liver Metastases

2020

<b><i>Background:</i></b> Hepatic steatosis and chemotherapy in the treatment of colorectal liver metastases (CLM) are often linked to increased mortality and morbidity after liver resection. This study evaluates the influence of macrovesicular hepatic steatosis and chemotherapeutic regimes on graded morbidity and mortality after liver resection for CLM. <b><i>Methods:</i></b> A total of 323 cases of liver resection for CLM were retrospectively analysed using univariable and multivariable linear, ordinal and Cox regression analyses. The resected liver tissue was re-evaluated by a single observer to determine the grade and type of hepatic steat…

Chemotherapymedicine.medical_specialtybusiness.industryProportional hazards modelColorectal cancermedicine.medical_treatmentGastroenterologymedicine.diseaseGastroenterologyOxaliplatinInternal medicineMedicineSurgerySteatosisRisk factorMacrovesicular hepatic steatosisbusinessPacked red blood cellsResearch Articlemedicine.drugVisceral Medicine
researchProduct

PREVALENCE OF HEPATIC STEATOSIS AND ITS RELATIONSHIP WITH CARDIOVASCULAR RISK IN HIV-PATIENTS WITH OR WITHOUT HCV CO-INFECTION

2012

HEPATIC STEATOSISCARDIOVASCULAR RISK HIV-PATIENTS HCV CO-INFECTION
researchProduct

Effect of aerobic exercise and diet on liver fat in pre-diabetic patients with non-alcoholic-fatty-liver-disease: A randomized controlled trial.

2017

AbstractThe study aimed to assess whether aerobic exercise (AEx) training and a fibre-enriched diet can reduce hepatic fat content (HFC) and increase glycaemic control in pre-diabetic patients with non-alcoholic fatty liver disease (NAFLD). Six-hundred-and-three patients from seven clinics in Yangpu district, Shanghai, China were recruited. Of them 115 individuals aged 50–65-year fulfilled the inclusion criteria (NAFLD with impaired fasting glucose or impaired glucose tolerance) and were randomly assigned into exercise (AEx n = 29), diet (Diet n = 28), exercise plus diet (AED n = 29), or no-intervention (NI n = 29) groups. Progressive supervised AEx training (60–75% VO2max intensity) was gi…

Lifestyle modificationMaleLIFE-STYLE INTERVENTIONSlcsh:MedicineruokavaliotGastroenterologyImpaired glucose tolerance0302 clinical medicineWeight lossNon-alcoholic Fatty Liver DiseaseMedicinelcsh:Science10. No inequalityIN-VIVOAdipositySPECTROSCOPYMultidisciplinaryINSULIN SENSITIVITYdietary fibreFatty liverrasvamaksaMiddle Aged3. Good healthIntention to Treat AnalysisTreatment OutcomeLiverdietsDisease Progression030211 gastroenterology & hepatologyFemaleaerobic trainingmedicine.symptommedicine.medical_specialtyTYPE-2 DIABETES-MELLITUSWEIGHT-LOSS030209 endocrinology & metabolismArticlePrediabetic State03 medical and health sciencesIMPAIRED GLUCOSE-TOLERANCEInsulin resistanceInternal medicineAerobic exerciseHumansHEPATIC STEATOSISExercise physiologyExerciseMETAANALYSISfatty liverGlycated HemoglobinIntention-to-treat analysisHepatologybusiness.industrylcsh:Raerobinen harjoittelumedicine.diseaseImpaired fasting glucoseDietravintokuitulcsh:QNORDIC WALKINGInsulin ResistancebusinessBiomarkersScientific reports
researchProduct

Non-invasive assessment of liver steatosis and fibrosis in HIV/HCV- and HCV- infected patients

2013

BACKGROUND: Conflicting data have been reported on the prevalence of liver steatosis, its risk factors and its relationship with fibrosis in patients with human immunodeficiency virus (HIV)/hepatitis C virus (HCV) co-infection or with HCV mono-infection. AIM: The study aims were to assess steatosis prevalence and its risk factors in both HCV groups. We also evaluated whether steatosis was linked with advanced fibrosis. Sixty-eight HIV/HCV co-infected and 69 HCV mono-infected patients were consecutively enrolled. They underwent liver ultrasonography and transient elastography. Bright liver echo-pattern was used to diagnose steatosis; advanced fibrosis was defined as liver stiffness ≥ 9.5 kPa…

Liver CirrhosisMaleHepatic steatosisTransient elastographySpecialties of internal medicineHIV Infectionsmedicine.disease_causeGastroenterologyRisk FactorsFibrosisPrevalenceFIB–4CoinfectionGeneral MedicineHepatitis CMiddle AgedItalyRC581-951Area Under CurveFIB-4Elasticity Imaging TechniquesFemaleLipodystrophyAdultmedicine.medical_specialtyHepatitis C virusLiver fibrosisHepatic steatosiWhite PeopleHIV/HCV co-infectionPredictive Value of TestsInternal medicinemedicineHumansChi-Square DistributionHepatologybusiness.industryLiver fibrosiHepatitis C Chronicmedicine.diseaseImpaired fasting glucoseFatty LiverLogistic ModelsROC CurveMultivariate AnalysisSteatosisMetabolic syndromeTransient elastographybusinessBiomarkersAnnals of Hepatology
researchProduct

Microsomal triglyceride transfer protein gene mutations in Turkish children: A novel mutation and clinical follow up.

2016

Abetalipoproteinemia (ABL; OMIM 200100) is a rare autosomal recessive disease that affects the absorption of dietary fats and fat soluble vitamins. Here, we describe the clinical and genetic characteristics of three patients with ABL. Two patients (patients 1 and 2) who were carriers of the c.398-399delAA mutation (previously known mutation) had developmental delay and hepatic steatosis developed at the age of five in patient 1. Patient 3 was the carrier of a novel mutation (g.10886-10902delAAGgtaagtttgtgttg in intron 3 and c.506A>T exon 5) in microsomal triglyceride transfer protein (MTP) gene and had hepatic steatosis.

Male0301 basic medicineHeterozygotemedicine.medical_specialtySettore MED/09 - Medicina InternaTurkeyDevelopmental delayDevelopmental DisabilitiesTurkish030204 cardiovascular system & hematologyHepatic steatosimedicine.disease_causeMicrosomal triglyceride transfer protein03 medical and health sciencesExon0302 clinical medicineInternal medicineHumansMedicineGeneGenetic Association StudiesGeneticsMutationABLbiologyAbetalipoproteinemiaDevelopmental delayHepatic steatosisMicrosomal triglyceride transfer proteinTurkishbusiness.industryIntronGastroenterologyInfantAbetalipoproteinemiaMicrosomal triglyceride transfer proteinmedicine.diseaseIntronsAbetalipoproteinemiaFatty Liver030104 developmental biologyEndocrinologyMutationbiology.proteinFemaleSteatosisCarrier ProteinsbusinessFollow-Up Studies
researchProduct

Metabolic syndrome triggered by high-fructose diet favors choroidal neovascularization and impairs retinal light sensitivity in the rat

2014

Diabetic retinopathy and age-related macular degeneration are the leading causes of blindness in Western populations. Although it is a matter of controversy, large-scale population-based studies have reported increased prevalence of age-related macular degeneration in patients with diabetes or diabetic retinopathy. We hypothesized that metabolic syndrome, one of the major risk factors for type 2 diabetes, would represent a favorable environment for the development of choroidal neovascularization, the main complication of age-related macular degeneration. The fructose-fed rat was used as a model for metabolic syndrome in which choroidal neovascularization was induced by laser photocoagulatio…

MaleOrganes des sensmedicine.medical_treatment[ SDV.AEN ] Life Sciences [q-bio]/Food and NutritionVisual Acuitylcsh:MedicineGene ExpressionType 2 diabetesinduced insulin-resistanceanimal-modelscholesterol homeostasis0302 clinical medicineRetinal Rod Photoreceptor CellsRats Inbred BNHyperinsulinemiaMedicine and Health Sciencesanimal modèleratlcsh:Science2. Zero hungerMetabolic Syndrome0303 health scienceseducation.field_of_studyMultidisciplinaryLaser Coagulationsyndrome métaboliqueReverse Transcriptase Polymerase Chain Reactionhepatic steatosisFatty AcidsAngiographyDiabetic retinopathyChoroidal neovascularizationAdipose Tissue[ SDV.MHEP.OS ] Life Sciences [q-bio]/Human health and pathology/Sensory OrgansAlimentation et NutritionRetinal Disordersmedicine.symptomLaser coagulationResearch Articlediabètemedicine.medical_specialtymacular degenerationPopulationSensory Organselectroretinographic oscillatory potentials;induced insulin-resistance;fatty-acid profile;macular degeneration;diabetic-retinopathy;animal-models;cholesterol homeostasis;hepatic steatosis;mouse;associationAntigens Differentiation MyelomonocyticMédecine humaine et pathologieFructoseBiologyRetina03 medical and health sciencesAntigens CDDiabetes mellitusInternal medicine[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathologymedicineElectroretinographyelectroretinographic oscillatory potentialsAnimalsHumansFood and Nutrition[SDV.MHEP.OS]Life Sciences [q-bio]/Human health and pathology/Sensory OrganseducationRetinopathymouse030304 developmental biologyNutritiondiabetic-retinopathylcsh:RassociationBiology and Life Sciencesdégénérescence maculaireMacular degenerationmedicine.diseaseChoroidal Neovascularizationeye diseasesDietFatty LiverOphthalmologyEndocrinologyMetabolic Disordersfatty-acid profile030221 ophthalmology & optometrylcsh:QInsulinomaHuman health and pathologysense organs[SDV.AEN]Life Sciences [q-bio]/Food and Nutrition[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

UNRAVELLING THE ROLES OF THE NUCLEAR PROTEIN 1 DURING ER-STRESS INDUCTION

2020

Background: NUPR1 was described as a transcriptional factor involved in the regulation of various cellular stress-response genes, playing a crucial role in the condition of the endoplasmic-reticulum (ER) stress, thus emerging as a common molecular factor of different pathologies, obesity, hepatic steatosis, and cancer. In the present work we aim to explore how NUPR1 interacts with some pivotal genes that are the major modulators of the ER stress and metabolic cell functions. In particular we investigated the biochemical and molecular effects arising from the loss of NUPR1 in ER stress physiological conditions. Methods: We used prolonged high fat diet (HFD) feeding to induce ER stress physio…

Settore MED/06 - Oncologia MedicaNuclear protein 1 P8 NUPR1 ER stress ATF6 PERK EIF2alfa cancer obesity hepatic steatosis mouse model metabolism geneSettore BIO/11 - Biologia Molecolare
researchProduct

Long-term hepatic safety of lomitapide in homozygous familial hypercholesterolaemia

2023

Introduction: Lomitapide is a microsomal triglyceride transfer protein inhibitor for patients with homozygous familial hypercholesterolaemia. Due to its mechanism of action, potential hepatic effects of lomitapide are of clinical interest. This study aimed to determine the long-term hepatic safety of lomitapide. Methods: Data were aggregated from the pivotal phase 3 and extension phase clinical trial with lomitapide (median 5.1 years; serum total bilirubin, transaminases, cytokeratin-18 [CK-18] and enhanced liver fibrosis [ELF] score, fat-soluble vitamins and essential fatty acids), 8-year data from the Lomitapide Observational Worldwide Evaluation Registry (LOWER) and real-world evidence f…

Settore MED/09 - Medicina Internahepatic steatosisliverLomitapidehepatic biomarkershepatic steatosiSettore BIO/18 - Geneticahepatic biomarkerSettore BIO/14 - Farmacologialiver fibrosis.hepatichepatic; hepatic biomarkers; hepatic steatosis; homozygous familial hypercholesterolaemia; liver; liver fibrosis; lomitapidehomozygous familial hypercholesterolaemialiver fibrosis
researchProduct

Creatine consumption and liver disease manifestations in individuals aged 12 years and over

2022

Despite the overwhelming safety evidence concerning creatine intake in various settings, there is still incomplete information whether dietary creatine affects liver health at the population level. The main aim of this cross-sectional population-based study was to evaluate the association between creatine intake through regular diet and liver disease manifestations, including liver fibrosis and hepatic steatosis, among individuals aged 12 years and over, using open-source data from the 2017–2018 U.S. National Health and Nutrition Examination Survey (NHANES). A total of 9254 male and female participants of all ages were included in the 2017–2018 NHANES round. We extracted data from the total…

VDP::Medisinske Fag: 700::Helsefag: 800::Ernæring: 811VDP::Medisinske Fag: 700::Helsefag: 800Food Scienceliver fibrosis ; diet ; blood liver panel ; hepatic steatosis ; NHANES ; creatine
researchProduct

Dual-release hydrocortisone improves hepatic steatosis in patients with secondary adrenal insufficiency: A real-life study

2019

Background:Conventional glucocorticoid treatment has a significant impact on liver in patients with adrenal insufficiency. Dual-release hydrocortisone (DR-HC) provides physiological cortisol exposure, leading to an improvement in anthropometric and metabolic parameters. We aimed to evaluate the effects of 12-month DR-HC treatment on the hepatic steatosis index (HSI), a validated surrogate index of hepatic steatosis, in patients with secondary adrenal insufficiency (SAI).Methods:A total of 45 patients with hypopituitarism, 22 with hypogonadism, hypothyroidism, ACTH, and GH deficiencies, and 23 with hypogonadism, hypothyroidism, and ACTH deficiency, on replacement therapy for all the pituitar…

medicine.medical_specialtySecondary adrenal insufficiencyEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismHypopituitarismHepatic steatosilcsh:Diseases of the endocrine glands. Clinical endocrinologyHypopituitarismSettore MED/13 - Endocrinologia03 medical and health sciences0302 clinical medicineInternal medicinemedicineAdrenal insufficiencyIn patientHydrocortisoneOriginal Researchlcsh:RC648-665business.industryhepatic steatosismedicine.diseaseInsulin sensitivityEndocrinology030220 oncology & carcinogenesisDual-release hydrocortisoneSteatosisLife studybusinessGlucocorticoidmedicine.drugSecondary adrenal insufficiency
researchProduct